DE3146841A1 - Wound-treatment compositions - Google Patents
Wound-treatment compositionsInfo
- Publication number
- DE3146841A1 DE3146841A1 DE19813146841 DE3146841A DE3146841A1 DE 3146841 A1 DE3146841 A1 DE 3146841A1 DE 19813146841 DE19813146841 DE 19813146841 DE 3146841 A DE3146841 A DE 3146841A DE 3146841 A1 DE3146841 A1 DE 3146841A1
- Authority
- DE
- Germany
- Prior art keywords
- gelatin
- wound treatment
- wound
- treatment agent
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 32
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title abstract description 3
- 229920000159 gelatin Polymers 0.000 claims abstract description 21
- 235000019322 gelatine Nutrition 0.000 claims abstract description 21
- 108010010803 Gelatin Proteins 0.000 claims abstract description 20
- 239000008273 gelatin Substances 0.000 claims abstract description 20
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 238000004132 cross linking Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims description 4
- -1 dicarboxylic acid chlorides Chemical class 0.000 claims description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 4
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 125000005442 diisocyanate group Chemical group 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000000645 desinfectant Substances 0.000 claims description 2
- 229940015043 glyoxal Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 2
- 239000007863 gel particle Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 229920001605 Dextranomer Polymers 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0038—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Neues Wundbehand lungsmittel. New wound treatment agent.
Die Erfindung betrifft ein Wundbehandlungsmittel, seine Verwendung sowie ein Verfahren zu seiner Herstellung. The invention relates to a wound treatment agent and its use and a method for its production.
Es ist bekannt, daß man die Wundheilung bei schwer heilenden Wunden, wie Ulcera, diabetischem Gangräen, Verbrennungen oder infizierten Wunden unterstützen kann, indem man die Wunden mit trocknenden, dh. aufsaugenden, reinigenden und das Bakterienwachstum verhindernden Mitteln versorgt Verschiedenartige Wundbehandlungsmittel wurden bisher vorgeschlagen. It is known that wound healing in wounds that are difficult to heal, such as ulcers, diabetic gangrene, burns or infected wounds can by treating the wounds with drying, ie. absorbent, cleansing and that Bacterial Growth Preventive Agents supplies various wound treatment agents have been proposed so far.
Zumeist handelt es sich dabei um Polyzucker-Verbindungen, wie Dextranomere, wie beispielsweise in der US-PS 4 225 580 beschrieben. Daneben sind auch bereits vernetzte Stärke vorgeschlagen worden, vgl. DE-OS 2 908 437, sowie Polyvinylalkohol, vgl. EP-OS 22 064. Für die praktische Anwendung haben sich diese Mittel jedoch nicht in allen Fäilen als zufriedenstellend erwiesen. So erleiden die genannten, bekannten Hydrogele im Gewebe kaum oder nur einen extrem langsamen Abbau und es ist daher für eine gute Wundheilung erforderlich, solche Wundbehandlungsmittel wieder vollständig von der Wunde zu entfernen. Ebenso ist der günstige Effekt auf die Wundheilung selbst in vielen Fällen verbesserungswürdig.Mostly these are polysugar compounds, such as dextranomers, as described, for example, in U.S. Patent 4,225,580. Besides that are also already cross-linked starch has been proposed, see DE-OS 2 908 437, and polyvinyl alcohol, see EP-OS 22 064. However, these means have not been used in practice proved satisfactory in all cases. This is how the well-known people named suffer Hydrogels in the tissue hardly or extremely slow degradation and it is therefore For good wound healing, such wound treatment agents are required to be completely restored remove from the wound. Likewise, it has a beneficial effect on wound healing itself in many cases could be improved.
Aufgabe der Erfindung war es, ein Wundheilungsmittel zu schaffen, das die aufgezeigten Nachteile nicht, oder nicht in dem bekannten Maße aufweist. The object of the invention was to create a wound healing agent, which does not have the disadvantages indicated, or does not have the known extent.
Demgemäß betrifft die Erfindung ein Wundbehandlungsmittel, enthaltend quervernetzte Gelatine. Accordingly, the invention relates to a wound treatment agent containing cross-linked gelatin.
Wenn man Gelatine, beispielsweise in fester Form, als Pulver, Schuppen oder Granulat einer Vernetzung unterzieht, erhält man Produkte, die nicht mehr wasserlöslich sind, dafür aber die Eigenschaften mechanisch stabiler Gele besitzen, die je nach Vernetzungsgrad das 3 bis 8fache ihres Eigengewichts an Wasser absorbieren können. Die so erhaltene, quervernetzte Gelatine, insbesondere in Form von Pulver, Schuppen oder Granulat, ist aufgrund ihres hohen Wasser- und Sekretaufnahmevermögens in überraschend guter Weise geeignet, Wunden zu reinigen und zu trocknen, so daß eine verstärkte Wundgranulation und damit Heilung einsetzen kann. Dabei wird die erfindungsgemäß verwendete quervernetzte Gelatine je nach Vernetzungsgrad mehr oder weniger schnell vom Gewebe resorbiert, da die Grundstrukturen der Eiweißketten erhalten sind, so daß bei nicht vollständigem Auswaschen des Granulats verbleibende Reste im Gewebe abgebaut und resorbiert werden. If you have gelatin, for example in solid form, as a powder, flakes or granules are crosslinked, products are obtained that are no longer water-soluble are, but have the properties of mechanically stable gels, which depending on Degree of crosslinking can absorb 3 to 8 times their own weight in water. The cross-linked gelatin obtained in this way, especially in the form of powder, flakes or granules, is surprising due to their high water and secretion absorption capacity well suited to cleansing and drying wounds, so that a reinforced Wound granulation and thus healing can begin. In doing so, according to the invention used cross-linked gelatin more or less quickly depending on the degree of cross-linking absorbed by the tissue, since the basic structures of the protein chains are preserved, so that if the granulate is not completely washed out, residues remain in the tissue be broken down and reabsorbed.
Die erfindungsgemäß verwendete quervernetzte Gelatine wird in an sich bekannter Weise insbesondere durch Umsetzung von Gelatine mit Vernetzungsreagenzien, wie Formaldehyd, Glyoxal, Glutardialdehyd, Dicarbonsäurechloriden undioder Diisocyanaten erhalten. Dabei kann man vorteilhaft so vorgehen, daß man Gelatine in Form von Blättchen, Schuppen, Pulver oder Granulat in Eiswasser vorlegt und ohne vorherige Auflösung der Gelatine die Vernetzung durchführt. Besonders bevorzugt ist eine Vernetzung mit einem Diisocyanat, wie Hexamethylendiisocyanat. The crosslinked gelatin used according to the invention is in an known way, in particular by reacting gelatin with crosslinking reagents, such as formaldehyde, glyoxal, glutaraldehyde, dicarboxylic acid chlorides and / or diisocyanates obtain. It can be advantageous to proceed in such a way that gelatin in the form of flakes, Put flakes, powder or granules in ice water and do not dissolve beforehand the gelatin carries out the crosslinking. Crosslinking is particularly preferred with a diisocyanate such as hexamethylene diisocyanate.
Die erfindungsgemäße Verwendung der quervernetzten Gelatine in Wundbehandlungsmitteln kann insbesondere so erfolgen, daß man die Wunde mit dem Mittel in Pulverform bestreut, ohne daß die Wunde berührt wird. Anschließend wird mit einem leichten Verband gesichert. Aufgrund des hohen Saugvermögens des Wundbehandlungsmittels wird das mit Bakterien und nekrotischem Gewebe belastete Wundsekret vom Wundgrund weg in die Gelpartikel transportiert. so daß ein sauberer Wundgrund zurückbleibt. The use according to the invention of the crosslinked gelatin in wound treatment agents can in particular be carried out in such a way that the wound is sprinkled with the agent in powder form, without touching the wound. Then it is secured with a light bandage. Due to the high absorbency of the wound treatment agent, this becomes with bacteria and necrotic tissue loaded wound exudate away from the wound bed into the gel particles transported. so that a clean wound bed remains.
Dabei kann es vorteilhaft sein, dem erfindungsgemäßen Wundbehandlungsmittel weitere übliche Zusatzstoffe zuzusetzen, vor oder auch nach Vernetzung, beispielsweise Desinfektionsmittel und/oder Antibiotika.It can be advantageous to use the wound treatment agent according to the invention to add further customary additives, before or after crosslinking, for example Disinfectants and / or antibiotics.
Ein Verbandwechsel bzw. der Austausch der vollgesogenen Gelpartikel erfolgt vorteilhaft durch Aussprühen der Wunde mit physiologischer Kochsalziösung. Bei der Behandlung stark kontaminierter Wunden ist der Zusatz antimikrobiell wirkender Substanzen zum Granulat oder dergleichen besonders zweckmäßig. A dressing change or the exchange of the soaked gel particles is advantageously carried out by spraying the wound with physiological saline solution. When treating heavily contaminated wounds, the addition is more antimicrobial Substances for granules or the like are particularly useful.
Die folgenden Beispiele erläutern die Erfindung, wobei der Fachmann aufgrund seines Wissens Abwandlungen vornehmen kann, ohne die Erfindung zu verlassen. The following examples explain the invention to those skilled in the art can make modifications based on his knowledge without departing from the invention.
Beispiel 1 Gelatine gepulvert (10 g) wird in eine Mischung aus 100 g Eis und 100 g Wasser eingetragen und unter Rühren mit 0,5 g Hexamethylendiisocyanat vernetzt. Man läßt 3 Stunden bei Raumtemperatur reagieren und danach weitere 3 Stunden bei 400C. Die vernetzten Gelatinepartikei werden mit Isopropanol gewaschen und dann bei 50"C getrocknet. Man erhält ein weißgelbliches Pulver mit einem Wasseraufnahmevermögen von 7-8g/g, das sowohl in kaltem als auch heißem Wasser quillt aber uniöslich ist. Example 1 Powdered gelatin (10 g) is added to a mixture of 100 Added g of ice and 100 g of water and, with stirring, with 0.5 g of hexamethylene diisocyanate networked. The reaction is allowed to take place for 3 hours at room temperature and then for a further 3 hours at 400C. The crosslinked gelatin particles are washed with isopropanol and then dried at 50 ° C. A yellowish-white powder with a water absorption capacity is obtained of 7-8g / g, which swells in both cold and hot water but is insoluble.
Beispiel 2 15 g Blattgelatine werden in 400 g Eiswasser mit 1,0 g Hexamethylen diisocyanat 2 Stunden und dann weitere 3 Stunden bei Raumtemperatur gerührt. Die Lösung wird abgesaugt, der Rückstand mit Isopropanol gewaschen und bei 50"C getrocknet Man erhält Gelatineplättchen mit einem Wasseraufnahmevermögen von 6 - 7 g. Example 2 15 g of gelatine leaves are added to 400 g of ice water with 1.0 g Hexamethylene diisocyanate 2 hours and then a further 3 hours at room temperature touched. The solution is filtered off with suction, the residue is washed with isopropanol and dried at 50 ° C. This gives gelatin platelets with a water absorption capacity from 6 - 7 g.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813146841 DE3146841A1 (en) | 1981-11-26 | 1981-11-26 | Wound-treatment compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813146841 DE3146841A1 (en) | 1981-11-26 | 1981-11-26 | Wound-treatment compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3146841A1 true DE3146841A1 (en) | 1983-06-01 |
Family
ID=6147234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19813146841 Withdrawn DE3146841A1 (en) | 1981-11-26 | 1981-11-26 | Wound-treatment compositions |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3146841A1 (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0365705A1 (en) * | 1988-10-26 | 1990-05-02 | Zentralna Problemna Laboratoria Po Kryobiologia I Lyophilisazia | Biopreparation for the treatment of wounds |
| WO1992013578A1 (en) * | 1990-07-09 | 1992-08-20 | Bausch & Lomb Incorporated | A biologically derived medical adhesive and its uses |
| WO1997041899A1 (en) * | 1996-05-03 | 1997-11-13 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
| WO1998055161A1 (en) * | 1997-06-03 | 1998-12-10 | Innogenetics N.V. | New medicaments based on polymers composed of methacrylamide-modified gelatin |
| WO2005009448A1 (en) * | 2003-07-24 | 2005-02-03 | Ooo Delsi | Treatment of lesions of the soft tissues |
| US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
| US7923031B2 (en) | 2004-01-30 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic sprays and compositions |
| US7955288B2 (en) | 2002-12-11 | 2011-06-07 | Ferrosan Medical Devices A/S | Gelatine-based materials as swabs |
| US8021684B2 (en) | 2004-07-09 | 2011-09-20 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
| US8642831B2 (en) | 2008-02-29 | 2014-02-04 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
| US9265858B2 (en) | 2012-06-12 | 2016-02-23 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
| US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
| US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
| US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
| US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
| US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
| US12544483B2 (en) | 2023-09-20 | 2026-02-10 | Ethicon Inc. | Method for preparing a haemostatic composition |
-
1981
- 1981-11-26 DE DE19813146841 patent/DE3146841A1/en not_active Withdrawn
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0365705A1 (en) * | 1988-10-26 | 1990-05-02 | Zentralna Problemna Laboratoria Po Kryobiologia I Lyophilisazia | Biopreparation for the treatment of wounds |
| WO1992013578A1 (en) * | 1990-07-09 | 1992-08-20 | Bausch & Lomb Incorporated | A biologically derived medical adhesive and its uses |
| WO1997041899A1 (en) * | 1996-05-03 | 1997-11-13 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
| WO1998055161A1 (en) * | 1997-06-03 | 1998-12-10 | Innogenetics N.V. | New medicaments based on polymers composed of methacrylamide-modified gelatin |
| US6458386B1 (en) | 1997-06-03 | 2002-10-01 | Innogenetics N.V. | Medicaments based on polymers composed of methacrylamide-modified gelatin |
| US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
| US8283320B2 (en) | 2001-12-21 | 2012-10-09 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostasis |
| US7955288B2 (en) | 2002-12-11 | 2011-06-07 | Ferrosan Medical Devices A/S | Gelatine-based materials as swabs |
| WO2005009448A1 (en) * | 2003-07-24 | 2005-02-03 | Ooo Delsi | Treatment of lesions of the soft tissues |
| JP2006528622A (en) * | 2003-07-24 | 2006-12-21 | オーオーオー デルシ | Treatment of soft tissue damage |
| US7923031B2 (en) | 2004-01-30 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic sprays and compositions |
| US8021684B2 (en) | 2004-07-09 | 2011-09-20 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
| US8642831B2 (en) | 2008-02-29 | 2014-02-04 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
| US9533069B2 (en) | 2008-02-29 | 2017-01-03 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
| US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
| US9265858B2 (en) | 2012-06-12 | 2016-02-23 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| US10799611B2 (en) | 2012-06-12 | 2020-10-13 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
| US10595837B2 (en) | 2013-06-21 | 2020-03-24 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
| US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
| US11103616B2 (en) | 2013-12-11 | 2021-08-31 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
| US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
| US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
| US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
| US12544483B2 (en) | 2023-09-20 | 2026-02-10 | Ethicon Inc. | Method for preparing a haemostatic composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3146841A1 (en) | Wound-treatment compositions | |
| EP0543868B1 (en) | Dressing system | |
| AT393795B (en) | COHERENT, POROESIC COLLAGEN FILM MATERIAL AND METHOD FOR THE PRODUCTION THEREOF | |
| EP0048323B1 (en) | Product in powder form for the treatment of wounds, and method for the preparation thereof | |
| DE69321389T2 (en) | Hydrocolloid gel for wounds | |
| DE3608158C2 (en) | ||
| DE69523585T2 (en) | WOUND MEDICINE | |
| DE3444746A1 (en) | PROTEOLYTIC Wound Bandage And Its Manufacture | |
| DE69817574T2 (en) | MANUFACTURING METHOD FOR A FIBER-FREE, POROUS MATERIAL | |
| DE2849570C2 (en) | ||
| DE3203957C2 (en) | ||
| EP0075791A1 (en) | Absorbent wound dressing and processes for its production | |
| DD235827A5 (en) | METHOD FOR PRODUCING A RESORBIBLE ANTIBIOTIC DEPOT | |
| CH646607A5 (en) | HAEMOSTATIC AGENT AND METHOD FOR THE PRODUCTION THEREOF. | |
| DE3034273A1 (en) | REGENERATED COLLAGEN AND METHOD FOR THE PRODUCTION THEREOF | |
| DE69330727T2 (en) | Freeze-dried bandage | |
| DE102009036995B4 (en) | Collagen-based matrix for use as a restorative material and method of making the same | |
| DD145062A5 (en) | TRANSPARENT LIQUID ASSOCIATED MATERIAL | |
| DE69925757T2 (en) | DEXTRAN MALEIC ACID MONOESTER AND HYDROGELES THEREOF | |
| DE2635508A1 (en) | ANTISEPTIC BODY | |
| DE69231973T2 (en) | Absorbent wound filler | |
| DE2823620C2 (en) | Process for producing a porous collagen skin dressing material | |
| CH615099A5 (en) | ||
| DE2908437A1 (en) | NETWORKED HYDROXYAETHYL STARCH | |
| CH675833A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |